Biopharma Transcript

Stryker Corp SYK

NYSE · Approved · device-combination · EDGAR · Updated Nov 5, 2026

Stryker Corp (NYSE: SYK) is a drug developer. Its lead program, Versius Plus surgical robot (CMR Surgical partnership), is marketed for Surgical procedures (general robotics platform).

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

For subscribers